Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 77, Issue 1, 2006, Pages 22-28

  Soucy, Nicole V ^a,c   Riley, Jason P ^a   Templin, Michael V ^b   Geary, Richard ^b   De Peyster, Ann ^a   Levin, Arthur A ^b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

Antisense oligonucleotide; Fetus; Placental transfer; Tissue distribution

Indexed keywords

AFOVIRSEN; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; FEMALE; GEL ELECTROPHORESIS; KIDNEY; LIVER; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT;

ANIMALS; FEMALE; INFUSIONS, INTRAVENOUS; MATERNAL-FETAL EXCHANGE; OLIGONUCLEOTIDES; PLACENTA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 33645912056     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20067     Document Type: Article

References (22)

1. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190.
2. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89-94.
3. Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds JM, Barr WH. 1994. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharm Ther 56:641-646.
4. Crooke ST. 1995. Oligonucleotide therapeutics. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. New York: Wiley. p 863-900.
5. Crooke ST. 1998a. Basic principles of antisense therapeutics. In: Crooke ST, editor. Handbook of experimental pharmacology. Berlin: Springer-Verlag, p 1-50.
6. Crooke ST. 1998b. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 8:115-122.
7. Driver SE, Robinson GS, Flanagan J, Shen W, Smith EH, Thomas DW, Roberts PC. 1999. Oligonucleotide-based inhibition of embryonic gene expression. Nat Biotechnol 17:1184-1187.
8. Flanagan WM. 1998. Antisense comes of age. Cancer Metastasis Rev 17:169-176.
9. Gaudette MF, Hampikian G, Metelev V, Agrawal S, Crain WR. 1993. Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. Antisense Res Dev 3:391-397.
10. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. 1997. Antisense Oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokineric properties of phosphorothioate oligonucleotides. Anticancer Drug Des 12:383-393.
11. Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR. 1997. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
12. Henry SP, Mbnteith DK, Levin AA. 1997a. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligonucleotides. Anticancer Drug Design 12:395-408.
13. Henry SP, Zuckerman JE, Rojko J, Hall WC, Harman RJ, Kitchen D, Crooke ST. 1997b. Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des 12:1-14.
14. Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. 2004a. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res (Part B) Dev Reprod Toxicol 71:368-373.
15. Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. 2004b. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res (Part B) Dev Reprod Toxicol 71:359-367.
16. Hoar RM, Monie IW. 1981. Comparative development of specific organ systems. In: Kimmell CA, Beulke-Sam J, editors. Developmental toxicology. New York: Raven, p 13-33.
17. Isis Pharmaceuticals Inc. [Reproductive and developmental toxicity of oligonucleotides targeting human or murine ICAM-1]. Unpublished raw data.
18. Leeds JM, Graham MJ, Troung L, Cummins LL. 1996. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43.
19. Morgan DJ. 1997. Drug disposition in mother and fetus. Clin Exp Pharmacol Physiol 24:869-873.
20. Schneider H. 1991. Placental transport function. Reprod Fertil Dev 3:345-353.
21. Simone C, Derewlany LO, Koren G. 1994. Drug transfer across the placenta. Considerations in treatment and research. Clin Perinatol 21:463-481.
22. Srinivasan SK, Iversen P. 1995. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9:129-137.